- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: CD86.
Displaying page 1 of 1.
EudraCT Number: 2010-018491-24 | Sponsor Protocol Number: 31295 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:Vrije Universiteit Medical Center | |||||||||||||
Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells | |||||||||||||
Medical condition: patients with malignant bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001030-94 | Sponsor Protocol Number: KKS-227 | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:Philipps University Marburg | |||||||||||||
Full Title: Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory... | |||||||||||||
Medical condition: Chronic myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003213-18 | Sponsor Protocol Number: RHMCAN1129 | Start Date*: 2017-01-13 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
Medical condition: Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011662-28 | Sponsor Protocol Number: ABRACADABRA | Start Date*: 2009-11-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Exploratory study on inflammatory immune response related to endothelial dysfunction in HIV-infected na�ve patients treated with abacavir compared to tenofovir-based regimens. | |||||||||||||
Medical condition: HIV INFECTION | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002479-28 | Sponsor Protocol Number: MOL-ARDS-002 | Start Date*: 2015-09-24 | |||||||||||
Sponsor Name:Justus-Liebig University | |||||||||||||
Full Title: GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration | |||||||||||||
Medical condition: Pneumonia associated Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003613-19 | Sponsor Protocol Number: APHP210303 | Start Date*: 2021-12-07 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS | ||
Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000237-12 | Sponsor Protocol Number: IM103-402 | Start Date*: 2021-05-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a... | |||||||||||||
Medical condition: Adolescent Renal Allografts | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003317-33 | Sponsor Protocol Number: CyPep-1 | Start Date*: 2019-12-31 |
Sponsor Name:Cytovation ASA | ||
Full Title: A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and ... | ||
Medical condition: Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumors or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 that ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FR (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002067-10 | Sponsor Protocol Number: MSC-JIA | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Mesenchymal stromal cells for treatment of drug resistant pediatric Juvenile idiopathic arthritis | |||||||||||||
Medical condition: juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004998-33 | Sponsor Protocol Number: CAMN107ADE22T | Start Date*: 2016-06-24 |
Sponsor Name:University of Heidelberg | ||
Full Title: Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular ... | ||
Medical condition: CML-Patients in chronic phase having failed a prior attempt to stop imatinib or other TKIs therapy either within EURO-SKI or not and are pretreated at least one year with any TKI after 1st stop | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002714-23 | Sponsor Protocol Number: LLC1114 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
